Cinaciguat Restores Liver Clearance in Aged Rats

Researchers at the University of Southern California reported that an experimental drug helped aged rat livers clear amyloid-beta more effectively.

Updated on Nov. 6, 2026 in Alzheimer’s

Cinaciguat Restores Liver Clearance in Aged Rats

Researchers at the University of Southern California restored liver clearance function in aged rats using the experimental drug cinaciguat. Treatment halved blood levels of amyloid-beta 40 and lowered LDL cholesterol, according to a study published in the Journal of Biological Chemistry.

Why it matters

Amyloid-beta circulating in the blood is partly removed by the liver, and that clearance capacity declines with age. The findings suggest a possible route to lowering systemic amyloid-beta, though the study did not test effects on the brain.

The study reported a 50% reduction in blood amyloid-beta 40 in treated aged rats, based on three to six independent biological samples per condition. Whether these blood changes translate to brain outcomes has not been established.

The players

University of Southern California

A private research university in Los Angeles, California, whose researchers led the study on liver clearance in aged rats.

The details

Cinaciguat reopened microscopic openings in liver vessel-lining cells that had become smaller and fewer with age. The drug also restored release of the growth factor HB-EGF from these cells, renewing their communication with liver cells.

Daily dosing of two-year-old rats with cinaciguat lasted two weeks.
The study article was published on November 6, 2026.

Health Landscape

The amyloid cascade hypothesis has long centered Alzheimer's research on amyloid-beta accumulation in the brain. This liver-focused finding adds a peripheral clearance pathway to that framework, though it remains at the animal-study stage.

At this stage the findings do not change any treatment options or daily health routines for people with or at risk of Alzheimer's. Any future human therapy would require further research into effectiveness and safety.

The takeaway

Liver function may influence how the body clears amyloid-beta, a possibility worth watching as research moves toward disease models. Readers should treat these results as early, animal-based evidence rather than a treatment advance.